Will private equity get a crush on biotechnology?

Private equity funds have so far stayed noticeably cool towards biotech, and analysts have begun to question why. This analysis in the Chicago Tribune offers some interesting insights into how private equity could approach the industry. An advanced biotech company would offer high value to the investors, allowing them to "strip" out low profit programs and sell them. It could be that the private equity crowd is waiting for the biotech IPO market, which has been lackluster of late, to heat up.

- here's the analysis from the Chicago Tribune

Related Articles:
Private equity deal in works for Peptech? Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.